International Clinical Trial: A Phase II Study of Ivarmacitinib Combined with Camrelizumab and Fruquintinib for Patients with Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128602) titled 'A Phase II Study of Ivarmacitinib Combined with Camrelizumab and Fruquintinib for Patients with Metastatic Colorectal Cancer After Failure of Second-line or Later Treatment' on July 22.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Renmin Hospital of Wuhan University

Condition: Metastatic colorectal cancer

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2026-02-28

Target Sample Size: "Ivarmacitinib, Camrelizumab, and Fruquintinib" Combination Therapy Group:33;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?pr...